Covariates | Levels | Adjusted OR (95 % CI) | p value* | AuROC (95 % CI) with biomarker | AuROC (95 % CI) without biomarker | p value** | |
---|---|---|---|---|---|---|---|
Risk factors for acute kidney injurya | |||||||
Model I | Witnessed CAc | No/yes | 2.27 (0.85–6.07) | 0.104 | 0.747 (0.667-0.817) | 0.719 (0.649-0.790) | 0.084 |
(n = 195) | SOFA score day 0 | ≥/<10 | 3.08 (1.46–6.48) | 0.003 | |||
Urea day 0 | ≥/<6.7 mmol/L | 2.63 (1.40–4.95) | 0.003 | ||||
Admission cystatin C | ≥/<291/ng/mL | 2.42 (2.29–4.54) | 0.006 | ||||
Model II | Witnessed CAc | No/yes | 2.15 (0.80–5.77) | 0.128 | 0.752 (0.682-0.821) | 0.719 (0.649-0.790 | 0.046 |
(n = 195) | SOFA score day 0 | ≥/<10 | 2.94 (1.39–6.21) | 0.005 | |||
Urea day 0 | ≥/<6.7 mmol/L | 2.63 (1.40–4.95) | 0.003 | ||||
Admission NGAL | ≥/<219 ng/mL | 2.59 (1.37–4.89) | 0.004 | ||||
Model III | SOFA score day 0 | ≥/<10 | 2.76 (1.25–6.10) | 0.012 | 0.725 (0.644-0.806) | ||
(n = 164) | Urea day 0 | ≥/<6.7 mmol/L | 1.98 (1.00–3.93) | 0.049 | |||
Cystatin C day 3 | ≥/<59 ng/mL | 2.87 (1.45–5.70) | 0.003 | ||||
Model IV | SOFA score day 0 | ≥/<10 | 2.83 (1.24–6.50) | 0.014 | 0.774 (0.700-0.848) | ||
(n = 164) | Urea day 0 | ≥/<6.7 mmol/L | 2.82 (1.12–4.66) | 0.024 | |||
NGAL day 3 | ≥/<110 ng/mL | 5.46 (2.65–11.24) | <0.001 | ||||
Risk factors for mortalitya | |||||||
Model V | Initial VT/VFc | No/yes | 4.70 (2.27–9.74) | <0.001 | 0.811 (0.751-0.872) | 0.790 (0.727-0.852) | 0.141 |
(n = 195) | AKI within 3 days | Yes/no | 2.83 (1.40–5.69) | 0.004 | |||
SOFA sore day 0 | ≥/<10 | 3.40 (1.47–7.88) | 0.004 | ||||
Admission cystatin C | ≥/<291 ng/mL | 2.88 (1.44–5.77) | 0.003 | ||||
Model VI | Initial VT/VFc | No/yes | 4.11 (1.99–8.53) | <0.001 | 0.812 (0.751-0.873) | 0.790 (0.727-0.852) | 0.131 |
(n = 195) | AKI within 3 days | Yes/no | 2.86 (1.43–5.74) | 0.003 | |||
SOFA sore day 0 | ≥/<10 | 3.28 (1.43–7.50) | 0.005 | ||||
Admission NGAL | ≥/<219 ng/mL | 2.87 (1.44–5.72) | 0.003 | ||||
Model VII | Initial VT/VFc | No/yes | 3.13 (1.45–6.72) | 0.004 | 0.784 (0.713-0.854) | ||
(n = 164) | AKI within 3 days | Yes/no | 2.44 (1.16–5.13) | 0.019 | |||
SOFA sore day 0 | ≥/<10 | 2.67 (1.14–6.23) | 0.024 | ||||
Cystatin C day 3 | ≥/<59 ng/mL | 2.45 (1.17–5.13) | 0.018 | ||||
Model VIII | Initial VT/VFc | No/yes | 3.12 (1.45–6.69) | 0.004 | 0.785 (0.713-0.857) | ||
(n = 164) | AKI within 3 days | Yes/no | 2.06 (0.95–4.47) | 0.069 | |||
SOFA score day 0 | ≥/<10 | 2.88 (1.22–6.84) | 0.016 | ||||
NGAL day 3 | ≥/<110 ng/mL | 2.85 (1.32–6.14) | 0.008 | ||||
Risk factors for unfavourable neurological outcomea | |||||||
Model IX | Initial VT/VFc | No/yes | 5.07 (2.40–10.74) | <0.001 | 0.819 (0.759-0.878) | 0.810 (0.750-0.870) | 0.264 |
(n = 195) | AKI within 3 days | Yes/no | 2.67 (1.32–5.40) | 0.006 | |||
BE day 0 | </≥–7 mmol/L | 2.07 (1.00–4.26) | 0.050 | ||||
SOFA score day 0 | ≥/<10 | 2.45 (1.08–5.57) | 0.032 | ||||
Admission cystatin C | ≥/<291 ng/mL | 2.06 (1.00–4.25) | 0.050 | ||||
Model Xb | Initial VT/VFc | No/yes | 4.92 (2.35–10.38) | <0.001 | 0.810 (0.750-0.871) | ||
(n = 195) | AKI within 3 days | Yes/no | 3.03 (1.52–6.02) | 0.002 | |||
BE day 0 | </≥–7 mmol/L | 2.56 (1.29–5.09) | 0.007 | ||||
SOFA score day 0 | ≥/<10 | 2.48 (1.11–5.54) | 0.027 | ||||
Model XI | Initial VT/VFc | No/yes | 3.42 (1.58–7.39) | 0.002 | 0.778 (0.707-0.849) | ||
(n = 164) | AKI within 3 days | Yes/no | 2.45 (1.17–5.12) | 0.017 | |||
BE day 0 | </≥–7 mmol/L | 2.53 (1.24–5.18) | 0.011 | ||||
Cystatin C day 3 | ≥/<59 ng/mL | 2.25 (1.09–4.65) | 0.029 | ||||
Model XII | Initial VT/VFc | No/yes | 3.77 (1.69–8.38) | 0.001 | 0.797 (0.729-0.866) | ||
(n = 164) | Fluid balance day 0 | ≥/<4.45 L/day | 2.12 (1.05–4.66) | 0.037 | |||
Urea day 0 | ≥/<6.7 mmol/L | 2.13 (1.03–4.43) | 0.043 | ||||
BE day 0 | </≥–7 mmol/L | 2.21 (1.06–4.62) | 0.035 | ||||
NGAL day 3 | ≥/<110 ng/mL | 3.41 (1.65–7.06) | 0.001 |